Showing results (211-220 of 250) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.Cancer Immunology, Immunotherapy : CII|April 19, 2020
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?Triantafyllia Koletsa, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.Plos One|August 1, 2018
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trialAnna Goussia, Nafsika Simou, Flora Zagouri, et al.Oncotarget|February 1, 2020
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine InitiativeElena Fountzilas, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.Pageof 25